|
Mar 12
|
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
|
|
Mar 12
|
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
Aug 8
|
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
|